10-Q · May 15, 2026
BioCardia reported net losses narrowing from $2.712 million in Q1 2025 to $2.259 million in Q1 2026, with no revenue noted again for this quarter. Operating expenses declined to $2.266 million from $2.726 million…
Earnings analysis · 10-Q
BCDA earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment data, or quantitative operating outlook, so quarter-over-quarter and year-over-year financial trends cannot be…
Read full summary
The provided 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment data, or quantitative operating outlook, so quarter-over-quarter and year-over-year financial trends cannot be assessed. Market-risk exposure appears limited, with a 100-basis-point rate shock described as immaterial and cash equivalents maturing in less than three months. The principal disclosed incremental risk is potential Nasdaq delisting if continued-listing compliance is not maintained.
What stood out
-
Limited Market-Risk Exposure
Management reported no material changes in market risk during the three months ended June 30, 2026. A hypothetical 100-basis-point interest-rate change would have an immaterial pre-tax impact on results.
-
Short-Dated Cash Portfolio
Cash equivalents have maturities of less than three months, supporting the company’s stated objectives of capital preservation and liquidity maintenance.
-
Controls Assessed Effective
The CEO and CFO concluded that disclosure controls were effective at a reasonable assurance level as of June 30, 2026, with no material changes to internal control during the three months ended June 30, 2026.
What to watch
-
Nasdaq Delisting Risk
The company states that it was previously not in compliance with Nasdaq continued-listing requirements and could face delisting if it fails to maintain compliance as of June 30, 2026. Delisting could reduce trading volume and security price and make capital raising more difficult.
-
Unhedged Interest-Rate Exposure
The company does not hedge interest-rate exposure. Although management considers the impact of a 100-basis-point rate change immaterial, future changes in rates could affect cash investment income and borrowing costs.
-
Foreign-Currency Exposure
The company has foreign-currency transactions and does not currently use hedging strategies. Management said exposure was not significant at June 30, 2026, but it continues to evaluate potential hedging.
Management's outlook
No quantitative revenue or EPS outlook is included in the provided 10-Q excerpt; outlook appears deferred to other company communications.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.